Apogee Therapeutics

News

Apogee buy delivers eczema trial win for AbbVie

AbbVie's long-acting IL-13 inhibitor zumilokibart, part of its $10.9bn Apogee buy, has shown efficacy in atopic dermatitis and will move into phase 3.

News

AbbVie climbs post-Allergan M&A peak with Apogee buy

AbbVie has announced its biggest acquisition since the $63 billion merger with Allergan, buying Apogee and its 'mega-blockbuster' immunology pipeline.

News

Apogee's chief executive Michael Henderson

Apogee rises as long-acting eczema drug heads for phase 3

Apogee shares have spiked on data showing strong efficacy with its atopic dermatitis drug and the potential for dosing just two to four times a year.

News

Apogee Therapeutics upsizes its IPO to $300m

In a small sign of a possible improvement in the sluggish biotech initial public offering (IPO) market, Apogee Therapeutics has said it expects gross proceeds of $300 mill

Apogee buy delivers eczema trial win for AbbVie

AbbVie climbs post-Allergan M&A peak with Apogee buy

Apogee rises as long-acting eczema drug heads for phase 3

Apogee Therapeutics upsizes its IPO to $300m

ESMO26: Taiho Oncology on improving the lives of patients wi...

Discover a new era of healthcare panel engagement: Grounded ...

Apogee Therapeutics

Editor's Picks